In order to identify the role of cN-II in cancer cells and during cancer treatment, we have initiated the search for cN-II inhibitors with the development of ribonucleoside phosphonate derivatives containing a chemically and enzymatically stable phosphonate (phosphorus-carbon) bond instead of the natural and labile phosphoester (phosphorus-oxygen) bond. Here, NT5C2 is linked to cancer.